Skip to main content
Journal of Patient-Reported Outcomes
Download PDF
Download ePub

Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL

Journal of Patient-Reported Outcomes volume 5, Article number: 73 (2021) Cite this article

The Original Article was published on 03 August 2021

Correction to: Journal of Patient-Reported Outcomes (2021) 5:65 https://doi.org/10.1186/s41687-021-00345-7


Following publication of the original article [1], the authors identified an error in the author name of G. Biolcati.


The incorrect author name is: G. Biolcatti


The correct author name is: G. Biolcati


The author group has been updated above and the original article [1] has been corrected.

Reference

  1. Biolcati G, Hanneken S, Minder EI et al (2021) Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. J Patient Rep Outcomes 5:65. https://doi.org/10.1186/s41687-021-00345-7

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Porphyrias, Istituto Dermatologico S. Gallicano - Istituti Fisioterapici Ospitalieri, Rome, Italy

    G. Biolcati

  2. Private Practice Empoderm, Düsseldorf, Germany

    S. Hanneken

  3. Stadtspital Triemli, Porphyria Outpatient Clinics, Zurich, Switzerland

    E. I. Minder

  4. Department of Dermatology, Heinrich Heine University, Duesseldorf, Germany

    N. J. Neumann

  5. The Department of Internal Medicine, Center of Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands

    J. H. P. Wilson

  6. Clinuvel Pharmaceuticals Limited, Melbourne, Australia

    P. J. Wolgen & D. J. Wright

  7. Acaster Lloyd Consulting Ltd, London, UK

    A. J. Lloyd

Authors
  1. G. Biolcati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Hanneken
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. I. Minder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. J. Neumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. H. P. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. J. Wolgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. J. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. J. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. J. Lloyd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biolcati, G., Hanneken, S., Minder, E.I. et al. Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. J Patient Rep Outcomes 5, 73 (2021). https://doi.org/10.1186/s41687-021-00348-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s41687-021-00348-4